Replimune Group (REPL) News Today $14.93 +3.88 (+35.11%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Replimune Group (NASDAQ:REPL) Hits New 12-Month High After Analyst UpgradeReplimune Group (NASDAQ:REPL) Reaches New 1-Year High on Analyst UpgradeNovember 22 at 11:39 AM | marketbeat.comBMO Capital Markets Raises Replimune Group (NASDAQ:REPL) Price Target to $18.00BMO Capital Markets raised their price target on shares of Replimune Group from $14.00 to $18.00 and gave the stock an "outperform" rating in a report on Friday.November 22 at 11:32 AM | marketbeat.comReplimune's stock surges 19% after-hours on FDA BLA submissionNovember 22 at 9:30 AM | msn.comReplimune Group (NASDAQ:REPL) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $17.00 price objective on shares of Replimune Group in a report on Friday.November 22 at 8:18 AM | marketbeat.comReplimune Group (REPL) Receives a Buy from J.P. MorganNovember 21 at 11:27 PM | markets.businessinsider.comReplimune Shares Top 52-Week High After Submitting Application for Melanoma TreatmentNovember 21 at 11:27 PM | marketwatch.comReplimune Group Advances Cancer Treatment with FDA SubmissionNovember 21 at 11:27 PM | markets.businessinsider.comReplimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval PathwayNovember 21 at 4:05 PM | globenewswire.comInsider Selling: Replimune Group, Inc. (NASDAQ:REPL) Insider Sells 7,246 Shares of StockNovember 21 at 8:35 AM | insidertrades.comReplimune Group, Inc. (NASDAQ:REPL) Shares Acquired by LMR Partners LLPLMR Partners LLP increased its stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 145.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 82,479 shares of the company's stock after purchasing an addNovember 20 at 4:55 AM | marketbeat.comQ3 EPS Estimates for Replimune Group Lifted by HC WainwrightNovember 17, 2024 | americanbankingnews.comReplimune Group Q3 EPS Estimate Lowered by Leerink PartnrsNovember 16, 2024 | americanbankingnews.comReplimune Group Q3 EPS Estimate Boosted by HC WainwrightReplimune Group, Inc. (NASDAQ:REPL - Free Report) - Stock analysts at HC Wainwright upped their Q3 2025 earnings per share estimates for shares of Replimune Group in a note issued to investors on Tuesday, November 12th. HC Wainwright analyst R. Burns now expects that the company will post earningNovember 15, 2024 | marketbeat.comReplimune Group Q3 EPS Forecast Lowered by Leerink PartnrsReplimune Group, Inc. (NASDAQ:REPL - Free Report) - Leerink Partnrs lowered their Q3 2025 earnings per share estimates for Replimune Group in a research report issued on Tuesday, November 12th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of ($0.71) fNovember 15, 2024 | marketbeat.comQ3 Earnings Estimate for Replimune Group Issued By WedbushReplimune Group, Inc. (NASDAQ:REPL - Free Report) - Equities research analysts at Wedbush upped their Q3 2025 earnings per share (EPS) estimates for Replimune Group in a note issued to investors on Tuesday, November 12th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($0.November 15, 2024 | marketbeat.comReplimune Group’s Q3 2024 Financial HighlightsNovember 15, 2024 | markets.businessinsider.comReplimune Group’s Strategic Progress and Financial Strength Justify Buy Rating and Increased Price TargetNovember 15, 2024 | markets.businessinsider.comBrokerages Set Replimune Group, Inc. (NASDAQ:REPL) Target Price at $16.80November 15, 2024 | americanbankingnews.comReplimune Group Navigates Clinical, Regulatory, and Market Challenges Amid Global UncertaintiesNovember 13, 2024 | markets.businessinsider.comReplimune Group’s Strategic Progress and Positive Outlook in Regulatory and Market PreparationsNovember 13, 2024 | markets.businessinsider.comReplimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate UpdateNovember 12, 2024 | finance.yahoo.comReplimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by AnalystsReplimune Group, Inc. (NASDAQ:REPL - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six analysts that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendationNovember 12, 2024 | marketbeat.comReplimune Group (NASDAQ:REPL) Sets New 1-Year High - Should You Buy?Replimune Group (NASDAQ:REPL) Reaches New 12-Month High - Here's WhyNovember 11, 2024 | marketbeat.comReplimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)November 9, 2024 | globenewswire.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 8, 2024 | globenewswire.comReplimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)October 30, 2024 | globenewswire.comReplimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of "Buy" by AnalystsShares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) have been given an average recommendation of "Buy" by the six ratings firms that are currently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating and one has assigned a stronOctober 18, 2024 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Down 5.2% - Here's What HappenedReplimune Group (NASDAQ:REPL) Shares Down 5.2% - Here's What HappenedOctober 14, 2024 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC increased its stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 282.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,207 shares of the companyOctober 13, 2024 | marketbeat.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 9, 2024 | globenewswire.comDimensional Fund Advisors LP Has $5.50 Million Position in Replimune Group, Inc. (NASDAQ:REPL)Dimensional Fund Advisors LP lessened its stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 37.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 610,681 shares of the company's stock after selling 367,171 sharesOctober 9, 2024 | marketbeat.comMorgan Stanley's Strategic Reduction in Replimune Group Inc HoldingsOctober 7, 2024 | gurufocus.comMillennium Management LLC Acquires 2,656,173 Shares of Replimune Group, Inc. (NASDAQ:REPL)Millennium Management LLC raised its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 575.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,118,035 shares of the company's stock aOctober 4, 2024 | marketbeat.comReplimune Group (NASDAQ:REPL) Sees Strong Trading VolumeReplimune Group (NASDAQ:REPL) Sees Large Volume IncreaseOctober 2, 2024 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Shares Could Be 48% Below Their Intrinsic Value EstimateOctober 2, 2024 | finance.yahoo.comDeerfield Management Company L.P. Series C Has $264,000 Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)Deerfield Management Company L.P. Series C decreased its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 96.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,300 shares of the company's stocSeptember 29, 2024 | marketbeat.comPoint72 Asia Singapore Pte. Ltd. Takes $443,000 Position in Replimune Group, Inc. (NASDAQ:REPL)Point72 Asia Singapore Pte. Ltd. bought a new stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 49,261 shares of the company's stock, valued at approSeptember 26, 2024 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Up 3.8% on Analyst UpgradeReplimune Group (NASDAQ:REPL) Trading Up 3.8% Following Analyst UpgradeSeptember 25, 2024 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Buy" from AnalystsShares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) have been assigned an average rating of "Buy" from the six brokerages that are covering the stock, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendationSeptember 23, 2024 | marketbeat.comReplimune Group Inc (7R8.SG)September 19, 2024 | nz.finance.yahoo.comStrong Phase 2 Results and Regulatory Progress Fuel Buy Rating for Replimune GroupSeptember 18, 2024 | markets.businessinsider.comReplimune Group (NASDAQ:REPL) Shares Gap Up to $11.03Replimune Group (NASDAQ:REPL) Shares Gap Up to $11.03September 18, 2024 | marketbeat.comStrong Buy Rating for Replimune Group on Robust Clinical and Regulatory MilestonesSeptember 16, 2024 | markets.businessinsider.comReplimune Group (NASDAQ:REPL) Stock Price Down 6.4%Replimune Group (NASDAQ:REPL) Shares Down 6.4%September 16, 2024 | marketbeat.comReplimune Group (NASDAQ:REPL) Rating Reiterated by HC WainwrightHC Wainwright reissued a "buy" rating and set a $17.00 price objective on shares of Replimune Group in a research report on Monday.September 16, 2024 | marketbeat.comReplimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024September 15, 2024 | globenewswire.comAcadian Asset Management LLC Buys 71,867 Shares of Replimune Group, Inc. (NASDAQ:REPL)Acadian Asset Management LLC increased its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 63.2% in the second quarter, according to its most recent filing with the SEC. The fund owned 185,516 shares of the company's stock after acquiring an additional 71,867 shares durinSeptember 15, 2024 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Up 7.4%Replimune Group (NASDAQ:REPL) Trading Up 7.4%September 13, 2024 | marketbeat.comHC Wainwright Analysts Lift Earnings Estimates for Replimune Group, Inc. (NASDAQ:REPL)Replimune Group, Inc. (NASDAQ:REPL - Free Report) - HC Wainwright upped their Q2 2025 earnings per share (EPS) estimates for shares of Replimune Group in a research report issued to clients and investors on Tuesday, September 10th. HC Wainwright analyst R. Burns now anticipates that the company wSeptember 12, 2024 | marketbeat.comPositive Outlook for Replimune’s RP1 Fuels Buy Rating Amidst Progress Toward Accelerated ApprovalSeptember 11, 2024 | markets.businessinsider.com Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. REPL Media Mentions By Week REPL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REPL News Sentiment▼0.440.49▲Average Medical News Sentiment REPL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REPL Articles This Week▼213▲REPL Articles Average Week Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Vir Biotechnology News AlloVir News Atara Biotherapeutics News bluebird bio News Beam Therapeutics News Bausch Health Companies News Vera Therapeutics News Kymera Therapeutics News MorphoSys News Vericel News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REPL) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
